KYNTRA BIO ($KYNB) posted quarterly earnings results for Q2 2026 on Thursday, August 13th. The company reported earnings of -$4.68 per share, missing estimates of -$3.25 by $1.43. The company also reported revenue of $-1,470,000, missing estimates of $2,046,803 by $-3,516,803.
You can see Quiver Quantitative's $KYNB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KYNTRA BIO Insider Trading Activity
KYNTRA BIO insiders have traded $KYNB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $KYNB stock by insiders over the last 6 months:
- THANE WETTIG (CEO) purchased 2,800 shares for an estimated $19,852
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
KYNTRA BIO Hedge Fund Activity
We have seen 5 institutional investors add shares of KYNTRA BIO stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 32,502 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $220,363
- DRW SECURITIES, LLC removed 30,420 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $206,247
- UBS GROUP AG removed 19,734 shares (-71.5%) from their portfolio in Q2 2026, for an estimated $148,991
- CITADEL ADVISORS LLC removed 16,756 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $113,605
- GSA CAPITAL PARTNERS LLP added 15,697 shares (+inf%) to their portfolio in Q2 2026, for an estimated $118,512
- NORTHERN TRUST CORP removed 12,852 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $87,136
- SQUAREPOINT OPS LLC removed 12,186 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $82,621
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
KYNTRA BIO Price Targets
Multiple analysts have issued price targets for $KYNB recently. We have seen 2 analysts offer price targets for $KYNB in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Jay Olson from Oppenheimer set a target price of $35.0 on 07/07/2026
- Michael G. King Jr. from Rodman & Renshaw set a target price of $30.0 on 06/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
